Bifogade filer
Cinclus Pharma Interim Report January – September 2024
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Cinclus Pharma Holding AB (publ) via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Mid Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2024-11-14 08:00:00
“The need for new alternatives to PPIs is evident as PCABs are making great progress worldwide,” said Christer Ahlberg, CEO of Cinclus Pharma.
Financial Summary, July – September 2024
- Net sales amounted to 0 (0) TSEK.
- Operating profit (EBIT) amounted to -39,148 (-62,070) TSEK.
- The result for the period was -36,547 (-61,951) TSEK and earnings (loss) per share before and after dilution were -0.79 (-2.36) SEK.
- Total cash flow for the period amounted to -40,470 (43,404) TSEK.
- Cash and cash equivalents at the end of the period amounted to 644,264 (87,972) TSEK.
Financial Summary, January – September 2024
- Net sales amounted to 0 (5,959) TSEK.
- Operating profit (EBIT) amounted to -112,750 (-161,221) TSEK.
- The result for the period was -113,772 (-170,977) TSEK and earnings (loss) per share before and after dilution were -3.36 (-6.52) SEK.
- Total cash flow for the period amounted to 556,030 (-22,855) TSEK.
- Cash and cash equivalents at the end of the period amounted to 644,264 (87,972) TSEK.
Significant events during the period July – September 2024
- During July 1, 11 and 19, stabilization purchases of Cinclus Pharma’s share were made in accordance with the mandate of over-allotment option granted to Carnegie Investment Bank AB. On July 19, it was announced that the over-allotment option had not been exercised.
- On July 29, Cinclus Pharma announced that Swiss-based global company PSI CRO will serve as the clinical research organization (CRO) for the phase III program of the Company’s lead drug candidate, linaprazan glurate, for the treatment of eGERD.
- Cinclus Pharma announced on September 24 that the results of a Phase I study of the acid suppression effect of Cinclus Pharma’s PCAB linaprazan glurate will be presented at the leading congress United European Gastroenterology Week (UEG) October 12 - 15, 2024.
- On September 30, the company announced that the manufacturing of the Investigational Medicinal Product (IMP), to be used for the company’s upcoming phase III study of linaprazan glurate for eGERD, has been successfully completed. Thus, the company is following its time plan for recruiting the first patient in 2025.
Significant events after the end of the period
- On October 12, linaprazan glurate was presented at UEG, United European Gastroenterology Week.
- On October 29, it was announced that EMA and Cinclus Pharma are in agreement regarding the paediatric study plan for eGERD.
PRESENTATION OF THE INTERIM REPORT
A webcast will be held on November 14, 2024, at 10:00 via Inderes. Link to the event
https://financialhearings.com/event/51345